JP2024517418A5 - - Google Patents
Info
- Publication number
- JP2024517418A5 JP2024517418A5 JP2023564144A JP2023564144A JP2024517418A5 JP 2024517418 A5 JP2024517418 A5 JP 2024517418A5 JP 2023564144 A JP2023564144 A JP 2023564144A JP 2023564144 A JP2023564144 A JP 2023564144A JP 2024517418 A5 JP2024517418 A5 JP 2024517418A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tezeperumab
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178938P | 2021-04-23 | 2021-04-23 | |
| US63/178,938 | 2021-04-23 | ||
| PCT/US2022/025994 WO2022226339A1 (en) | 2021-04-23 | 2022-04-22 | Anti-tslp antibody compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517418A JP2024517418A (ja) | 2024-04-22 |
| JP2024517418A5 true JP2024517418A5 (https=) | 2025-04-30 |
Family
ID=81597810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564144A Pending JP2024517418A (ja) | 2021-04-23 | 2022-04-22 | 抗ｔｓｌｐ抗体組成物及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240190951A1 (https=) |
| EP (1) | EP4326766A1 (https=) |
| JP (1) | JP2024517418A (https=) |
| KR (1) | KR20240000537A (https=) |
| CN (1) | CN117203233A (https=) |
| AR (1) | AR125408A1 (https=) |
| AU (1) | AU2022262421A1 (https=) |
| BR (1) | BR112023021867A2 (https=) |
| CA (1) | CA3216655A1 (https=) |
| CL (1) | CL2023003155A1 (https=) |
| CO (1) | CO2023014181A2 (https=) |
| CR (1) | CR20230531A (https=) |
| IL (1) | IL307540A (https=) |
| JO (1) | JOP20230265A1 (https=) |
| MX (1) | MX2023012363A (https=) |
| PE (1) | PE20240068A1 (https=) |
| TW (1) | TW202308690A (https=) |
| UY (1) | UY39736A (https=) |
| WO (1) | WO2022226339A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| IL324470A (en) | 2023-05-18 | 2026-01-01 | Medimmune Llc | Treatment of corticosteroid-dependent asthma using anti-TSLP antibody |
| WO2025147632A1 (en) | 2024-01-05 | 2025-07-10 | Medimmune, Llc | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| CN102281901A (zh) * | 2008-11-20 | 2011-12-14 | 弗·哈夫曼-拉罗切有限公司 | 治疗性蛋白质制剂 |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| TWI593705B (zh) * | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| WO2015116315A1 (en) | 2014-01-29 | 2015-08-06 | Amgen Inc. | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
| FI3218005T3 (fi) * | 2014-11-12 | 2023-03-31 | Seagen Inc | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| KR102666879B1 (ko) * | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| ES2978396T3 (es) * | 2017-08-01 | 2024-09-11 | Amgen Inc | Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| TW202541859A (zh) | 2018-10-15 | 2025-11-01 | 美商安進公司 | 具有阻尼機構之藥物遞送裝置及自動注射器 |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| JP7562563B2 (ja) | 2019-04-30 | 2024-10-07 | アムジエン・インコーポレーテツド | バイオ医薬品生産における細胞株選択のためのデータ駆動予測モデリング |
| AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
-
2022
- 2022-04-22 EP EP22722640.4A patent/EP4326766A1/en active Pending
- 2022-04-22 US US18/287,593 patent/US20240190951A1/en active Pending
- 2022-04-22 AR ARP220101047A patent/AR125408A1/es unknown
- 2022-04-22 BR BR112023021867A patent/BR112023021867A2/pt unknown
- 2022-04-22 CN CN202280029246.4A patent/CN117203233A/zh active Pending
- 2022-04-22 MX MX2023012363A patent/MX2023012363A/es unknown
- 2022-04-22 CA CA3216655A patent/CA3216655A1/en active Pending
- 2022-04-22 JP JP2023564144A patent/JP2024517418A/ja active Pending
- 2022-04-22 PE PE2023002912A patent/PE20240068A1/es unknown
- 2022-04-22 CR CR20230531A patent/CR20230531A/es unknown
- 2022-04-22 AU AU2022262421A patent/AU2022262421A1/en active Pending
- 2022-04-22 TW TW111115482A patent/TW202308690A/zh unknown
- 2022-04-22 WO PCT/US2022/025994 patent/WO2022226339A1/en not_active Ceased
- 2022-04-22 KR KR1020237039567A patent/KR20240000537A/ko active Pending
- 2022-04-22 IL IL307540A patent/IL307540A/en unknown
- 2022-04-27 UY UY0001039736A patent/UY39736A/es unknown
-
2023
- 2023-10-22 JO JOJO/P/2023/0265A patent/JOP20230265A1/ar unknown
- 2023-10-23 CL CL2023003155A patent/CL2023003155A1/es unknown
- 2023-10-24 CO CONC2023/0014181A patent/CO2023014181A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517418A5 (https=) | ||
| AU2015370522B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| EP3896083B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| AU2008228823A1 (en) | Stable antibody formulations | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| KR20080096827A (ko) | 항체 제제 | |
| JP2025148430A (ja) | 多発性骨髄腫の処置方法 | |
| TW201520226A (zh) | 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體 | |
| AU2020409583A1 (en) | Canine interleukin-4 receptor alpha antibodies | |
| US11548942B2 (en) | Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody | |
| TW201628647A (zh) | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 | |
| TWI842699B (zh) | Gcgr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用 | |
| CN116406290A (zh) | 用于治疗慢性炎症性疼痛的抗il-36r抗体 | |
| US20240368249A1 (en) | Fusion proteins for treating atopic dermatitis | |
| KR20250044335A (ko) | 항-tl1a 항체 제형 | |
| TWI922320B (zh) | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 | |
| RU2838203C2 (ru) | Способы лечения множественной миеломы | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2026026827A1 (zh) | 抗il-5抗体制剂及其制备方法 | |
| HK40115478A (zh) | 抗cd22抗体的水性制剂及其用途 | |
| TW202612730A (zh) | Ｅｇｆｒ結合和／或補體活化抗體的給藥方案 | |
| JP2025536574A (ja) | 抗ｃｔｌａ抗体組成物及び関連方法 | |
| JP2017528523A (ja) | 線維性疾患の治療 | |
| EP4388004A1 (en) | Antibodies and igg fusion proteins with an extended half-life | |
| WO2022120014A1 (en) | Pharmaceutical compositions of a her2/neu antibody and use of the same |